Insider Selling: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Sells 10,500 Shares of Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Sarepta Therapeutics Stock Performance

SRPT opened at $125.76 on Wednesday. Sarepta Therapeutics, Inc. has a 1-year low of $89.92 and a 1-year high of $173.25. The company has a market capitalization of $12.01 billion, a price-to-earnings ratio of 100.61 and a beta of 0.77. The business has a 50 day moving average price of $123.42 and a two-hundred day moving average price of $131.52. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Analysts Set New Price Targets

SRPT has been the subject of a number of research reports. Evercore ISI lowered their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. StockNews.com downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Piper Sandler cut their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. UBS Group upped their target price on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. Finally, William Blair upgraded Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $178.71.

Institutional Trading of Sarepta Therapeutics

Several institutional investors have recently modified their holdings of the company. Garden State Investment Advisory Services LLC acquired a new position in Sarepta Therapeutics during the third quarter worth about $2,115,000. Tidal Investments LLC grew its stake in shares of Sarepta Therapeutics by 91.2% in the 3rd quarter. Tidal Investments LLC now owns 5,634 shares of the biotechnology company’s stock worth $704,000 after purchasing an additional 2,688 shares during the last quarter. World Investment Advisors LLC acquired a new position in shares of Sarepta Therapeutics in the 3rd quarter worth approximately $2,418,000. Sunbelt Securities Inc. raised its holdings in shares of Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 232 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Sarepta Therapeutics by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after purchasing an additional 44,306 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.